Adjuvant Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors: Is This the Preferred Option?

J Clin Oncol. 2020 Sep 10;38(26):3073-3074. doi: 10.1200/JCO.20.00702. Epub 2020 Jul 7.

Authors

Lawrence H Einhorn¹, Nabil Adra¹, Nasser Hanna¹, Craig Nichols¹

Affiliation

¹ Lawrence H. Einhorn, MD; Nabil Adra, MD; and Nasser Hanna, MD, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; and Craig Nichols, MD, SWOG Chair's Office and Testicular Cancer Commons, Portland, OR.

PMID: 32634334
DOI: 10.1200/JCO.20.00702

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Chemotherapy, Adjuvant
Cisplatin / therapeutic use
Etoposide / therapeutic use
Humans
Male
Neoplasms, Germ Cell and Embryonal* / drug therapy
Testicular Neoplasms* / drug therapy

Substances

Etoposide
Cisplatin

Supplementary concepts

Nonseminomatous germ cell tumor